Brentuximab vedotin + pembrolizumab in R/R cHL
Presented by Dr Hanne Massa (Jules Bordet Institute, Brussels, Belgium)
The current standard treatment for R/R cHL involves salvage chemotherapy followed by ASCT. However, the optimal salvage therapy regimen remains undefined. Recent evidence suggests that the combination of brentuximab vedotin (BV) with PD-1 inhibitors may yield promising outcomes in this context.
Dr Hanne Massa, a haematologist in training at the Jules Bordet Institute in Brussels, presented a single centre retrospective analysis evaluating the efficacy and safety of BV and pembrolizumab as salvage therapy prior to ASCT, followed by BV maintenance, in patients with R/R cHL.
References:
Massa H, EHA2024 #P1105
With the educational support of:
